Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
PRESS RELEASE Businesswire
Sep. 12, 2018, 07:00 AM
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced its poster presentation of the anti-fibrogenic effects of Namodenosen in NAFLD/NASH pre-clinical data at the Hepatic Fibrosis Single Topic Conference of the American Association for the Study of Liver Diseases (AASLD) to be held on September 14-15, 2018 at the Hyatt Regency DFW International Airport, DFW Airport, TX.
Can Fite will present data generated recently in histological studies utilizing the CCL4 NAFLD/NASH model, demonstrating a significant decrease in liver fibrosis upon chronic treatment with Namodenoson, as measured by Sirius Red staining followed by morphometric digital analysis. Similar data were also reproduced in a human hepato-stelatte cell line demonstrating significant decrease in a-SMA expression level, a specific fibrosis bio-marker. The molecular mechanism which confers the anti-fibrogenic effect of Namodenoson will be presented as well.
"Our presentation entitled: Namodenoson Anti-Fibrogenic Effect is Mediated via De-Regulation of the Wnt/ß-catenin Pathway, will highlight the anti-fibrogenic effects of Namodenosen and its anti-NAFLD/NASH effect in the CCI4 mouse model and in a hepato-stelatte human cell line," said Dr. Pnina Fishman, Chief Executive Officer of Can-Fite BioPharma.
Can-Fite’s current Phase II NAFLD/NASH study is being conducted in three Israeli sites, including Hadassah Medical Center, Jerusalem, and the Rabin Medical Center, Petach Tikva. The Company anticipates the completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multibillion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for rheumatoid arthritis and psoriasis. Can-Fite’s liver cancer drug, Namodenoson, is in Phase II trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, and for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: www.can-fite.com.作者: StephenW 时间: 2018-9-13 17:45